CARIS LIFE SCIENCES INC (CAI) Fundamental Analysis & Valuation

NASDAQ:CAI • US1421521071

Current stock price

19.2 USD
-0.31 (-1.59%)
At close:
19.16 USD
-0.04 (-0.21%)
After Hours:

This CAI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. CAI Profitability Analysis

1.1 Basic Checks

  • CAI had positive earnings in the past year.
  • In the past year CAI had a positive cash flow from operations.
  • In multiple years CAI reported negative net income over the last 5 years.
  • In multiple years CAI reported negative operating cash flow during the last 5 years.
CAI Yearly Net Income VS EBIT VS OCF VS FCFCAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2023 2024 2025 0 200M -200M -400M -600M

1.2 Ratios

  • CAI has a Return On Assets (-47.79%) which is comparable to the rest of the industry.
  • CAI has a Return On Equity (-93.18%) which is comparable to the rest of the industry.
  • CAI's Return On Invested Capital of 3.57% is amongst the best of the industry. CAI outperforms 88.97% of its industry peers.
Industry RankSector Rank
ROA -47.79%
ROE -93.18%
ROIC 3.57%
ROA(3y)-89.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CAI Yearly ROA, ROE, ROICCAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2023 2024 2025 0 500 1K 1.5K 2K

1.3 Margins

  • Looking at the Operating Margin, with a value of 5.56%, CAI belongs to the top of the industry, outperforming 89.36% of the companies in the same industry.
  • In the last couple of years the Operating Margin of CAI has declined.
  • CAI has a better Gross Margin (66.40%) than 78.92% of its industry peers.
Industry RankSector Rank
OM 5.56%
PM (TTM) N/A
GM 66.4%
OM growth 3YN/A
OM growth 5Y-34.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAI Yearly Profit, Operating, Gross MarginsCAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CAI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CAI is destroying value.
  • Compared to 1 year ago, CAI has more shares outstanding
  • Compared to 5 years ago, CAI has more shares outstanding
  • The debt/assets ratio for CAI has been reduced compared to a year ago.
CAI Yearly Shares OutstandingCAI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2023 2024 2025 50M 100M 150M 200M 250M
CAI Yearly Total Debt VS Total AssetsCAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • CAI has an Altman-Z score of 4.64. This indicates that CAI is financially healthy and has little risk of bankruptcy at the moment.
  • CAI's Altman-Z score of 4.64 is fine compared to the rest of the industry. CAI outperforms 72.92% of its industry peers.
  • CAI has a debt to FCF ratio of 5.67. This is a neutral value as CAI would need 5.67 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 5.67, CAI belongs to the best of the industry, outperforming 91.30% of the companies in the same industry.
  • A Debt/Equity ratio of 0.66 indicates that CAI is somewhat dependend on debt financing.
  • CAI has a worse Debt to Equity ratio (0.66) than 72.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 5.67
Altman-Z 4.64
ROIC/WACC0.38
WACC9.41%
CAI Yearly LT Debt VS Equity VS FCFCAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2023 2024 2025 0 500M -500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 7.85 indicates that CAI has no problem at all paying its short term obligations.
  • CAI's Current ratio of 7.85 is fine compared to the rest of the industry. CAI outperforms 70.41% of its industry peers.
  • A Quick Ratio of 7.35 indicates that CAI has no problem at all paying its short term obligations.
  • The Quick ratio of CAI (7.35) is better than 68.67% of its industry peers.
Industry RankSector Rank
Current Ratio 7.85
Quick Ratio 7.35
CAI Yearly Current Assets VS Current LiabilitesCAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CAI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 191.16% over the past year.
  • CAI shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.17% yearly.
  • Looking at the last year, CAI shows a decrease in Revenue. The Revenue has decreased by -1.64% in the last year.
  • CAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.83% yearly.
EPS 1Y (TTM)191.16%
EPS 3Y14.52%
EPS 5Y12.17%
EPS Q2Q%121.24%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y-2.37%
Revenue growth 5Y4.83%
Sales Q2Q%-28.96%

3.2 Future

  • The Earnings Per Share is expected to decrease by -19.81% on average over the next years. This is quite bad
  • The Revenue is expected to grow by 17.18% on average over the next years. This is quite good.
EPS Next Y83.59%
EPS Next 2Y44.25%
EPS Next 3Y19.27%
EPS Next 5Y-19.81%
Revenue Next Year5.75%
Revenue Next 2Y8.24%
Revenue Next 3Y5.04%
Revenue Next 5Y17.18%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAI Yearly Revenue VS EstimatesCAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
CAI Yearly EPS VS EstimatesCAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

9

4. CAI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 4.49, the valuation of CAI can be described as very cheap.
  • Compared to the rest of the industry, the Price/Earnings ratio of CAI indicates a rather cheap valuation: CAI is cheaper than 98.84% of the companies listed in the same industry.
  • CAI is valuated cheaply when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 2.16 indicates a rather cheap valuation of CAI.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CAI indicates a rather cheap valuation: CAI is cheaper than 99.42% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.69. CAI is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.49
Fwd PE 2.16
CAI Price Earnings VS Forward Price EarningsCAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CAI indicates a rather cheap valuation: CAI is cheaper than 90.14% of the companies listed in the same industry.
  • CAI's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CAI is cheaper than 91.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 81.11
EV/EBITDA 75.17
CAI Per share dataCAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as CAI's earnings are expected to grow with 19.27% in the coming years.
PEG (NY)0.05
PEG (5Y)0.37
EPS Next 2Y44.25%
EPS Next 3Y19.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CAI Dividend Analysis

5.1 Amount

  • CAI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAI Fundamentals: All Metrics, Ratios and Statistics

CARIS LIFE SCIENCES INC

NASDAQ:CAI (4/9/2026, 4:30:03 PM)

After market: 19.16 -0.04 (-0.21%)

19.2

-0.31 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners50.55%
Inst Owner Change0%
Ins Owners48.41%
Ins Owner Change6.67%
Market Cap5.43B
Revenue(TTM)812.03M
Net Income(TTM)-537.96M
Analysts85.71
Price Target33.46 (74.27%)
Short Float %6.26%
Short Ratio2.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)458.54%
Min EPS beat(2)138.66%
Max EPS beat(2)778.42%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)23.74%
Min Revenue beat(2)21.32%
Max Revenue beat(2)26.17%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.63%
PT rev (3m)-12.92%
EPS NQ rev (1m)-56.7%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)0%
EPS NY rev (3m)1.96%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0.79%
Revenue NY rev (3m)2.74%
Valuation
Industry RankSector Rank
PE 4.49
Fwd PE 2.16
P/S 6.68
P/FCF 81.11
P/OCF 65.25
P/B 9.4
P/tB 9.72
EV/EBITDA 75.17
EPS(TTM)4.28
EY22.29%
EPS(NY)8.91
Fwd EY46.39%
FCF(TTM)0.24
FCFY1.23%
OCF(TTM)0.29
OCFY1.53%
SpS2.87
BVpS2.04
TBVpS1.97
PEG (NY)0.05
PEG (5Y)0.37
Graham Number14.03
Profitability
Industry RankSector Rank
ROA -47.79%
ROE -93.18%
ROCE 4.52%
ROIC 3.57%
ROICexc 17.82%
ROICexgc 19.73%
OM 5.56%
PM (TTM) N/A
GM 66.4%
FCFM 8.24%
ROA(3y)-89.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y32.08%
ROICexc growth 3YN/A
ROICexc growth 5Y29.42%
OM growth 3YN/A
OM growth 5Y-34.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 5.67
Debt/EBITDA 5.59
Cap/Depr 71.9%
Cap/Sales 2%
Interest Coverage 1.04
Cash Conversion 122.78%
Profit Quality N/A
Current Ratio 7.85
Quick Ratio 7.35
Altman-Z 4.64
F-Score6
WACC9.41%
ROIC/WACC0.38
Cap/Depr(3y)44.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)191.16%
EPS 3Y14.52%
EPS 5Y12.17%
EPS Q2Q%121.24%
EPS Next Y83.59%
EPS Next 2Y44.25%
EPS Next 3Y19.27%
EPS Next 5Y-19.81%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y-2.37%
Revenue growth 5Y4.83%
Sales Q2Q%-28.96%
Revenue Next Year5.75%
Revenue Next 2Y8.24%
Revenue Next 3Y5.04%
Revenue Next 5Y17.18%
EBIT growth 1Y117.55%
EBIT growth 3YN/A
EBIT growth 5Y-20.16%
EBIT Next Year16715.2%
EBIT Next 3Y608.87%
EBIT Next 5Y254.13%
FCF growth 1Y126.37%
FCF growth 3YN/A
FCF growth 5Y3.07%
OCF growth 1Y133.91%
OCF growth 3YN/A
OCF growth 5Y-21.39%

CARIS LIFE SCIENCES INC / CAI Fundamental Analysis FAQ

What is the fundamental rating for CAI stock?

ChartMill assigns a fundamental rating of 5 / 10 to CAI.


Can you provide the valuation status for CARIS LIFE SCIENCES INC?

ChartMill assigns a valuation rating of 9 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Undervalued.


What is the profitability of CAI stock?

CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 4 / 10.


What is the valuation of CARIS LIFE SCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CARIS LIFE SCIENCES INC (CAI) is 4.49 and the Price/Book (PB) ratio is 9.4.


Is the dividend of CARIS LIFE SCIENCES INC sustainable?

The dividend rating of CARIS LIFE SCIENCES INC (CAI) is 0 / 10 and the dividend payout ratio is 0%.